OBJECTIVE: Reverse cholesterol transport is the process by which excess cholesterol is removed from peripheral tissue by HDL and delivered to the liver for excretion. Presently, methods of measuring in vivo reverse cholesterol transport do so by monitoring the appearance in the feces of labeled cholesterol that originated from peripheral macrophage foam cells. These methods do not account for changes in macrophage cholesterol mass. We have developed an in vivo assay to measure cholesterol mass changes in atherosclerotic foam cells. METHODS AND RESULTS: Macrophages are entrapped in semipermeable (pore size 0.2 μm) hollow fibers and surgically implanted into the peritoneum of recipient mice. The fibers are removed from the peritoneum 24 hours after implantation. This method allows the complete recovery of the macrophages for quantification of changes in cholesterol mass and cellular protein. In wild-type mice we measured a significant reduction in total cell cholesterol (TC) when hollow fibers containing cholesterol-enriched macrophage cells were implanted (TC before implantation=105±18 μg/mg cell protein, TC 24 hours after implantation=60±16 μg/mg protein). Additionally, there was an increase in cholesterol content when hollow fibers containing cholesterol-normal macrophages were implanted in an atherogenic mouse model (LDLr/apobec dko) compared to a wild-type mouse (initial TC content=57±24 μg/mg protein, TC 24 hours after implantation: wild-type mice=52±10 μg/mg protein; LDLr/apobec dko mice=118±27 μg/mg protein). CONCLUSIONS: This assay can quantify in vivo both cholesterol mass accumulation, and reduction, in macrophages. This method permits quantitative analysis of the progression and regression of foam cells.
OBJECTIVE: Reverse cholesterol transport is the process by which excess cholesterol is removed from peripheral tissue by HDL and delivered to the liver for excretion. Presently, methods of measuring in vivo reverse cholesterol transport do so by monitoring the appearance in the feces of labeled cholesterol that originated from peripheral macrophage foam cells. These methods do not account for changes in macrophage cholesterol mass. We have developed an in vivo assay to measure cholesterol mass changes in atherosclerotic foam cells. METHODS AND RESULTS: Macrophages are entrapped in semipermeable (pore size 0.2 μm) hollow fibers and surgically implanted into the peritoneum of recipient mice. The fibers are removed from the peritoneum 24 hours after implantation. This method allows the complete recovery of the macrophages for quantification of changes in cholesterol mass and cellular protein. In wild-type mice we measured a significant reduction in total cell cholesterol (TC) when hollow fibers containing cholesterol-enriched macrophage cells were implanted (TC before implantation=105±18 μg/mg cell protein, TC 24 hours after implantation=60±16 μg/mg protein). Additionally, there was an increase in cholesterol content when hollow fibers containing cholesterol-normal macrophages were implanted in an atherogenic mouse model (LDLr/apobec dko) compared to a wild-type mouse (initial TC content=57±24 μg/mg protein, TC 24 hours after implantation: wild-type mice=52±10 μg/mg protein; LDLr/apobec dko mice=118±27 μg/mg protein). CONCLUSIONS: This assay can quantify in vivo both cholesterol mass accumulation, and reduction, in macrophages. This method permits quantitative analysis of the progression and regression of foam cells.
Authors: Sandhya Sankaranarayanan; Margarita de la Llera-Moya; Denise Drazul-Schrader; Bela F Asztalos; Ginny L Weibel; George H Rothblat Journal: J Lipid Res Date: 2010-08-16 Impact factor: 5.922
Authors: Edward A Fisher; Jonathan E Feig; Bernd Hewing; Stanley L Hazen; Jonathan D Smith Journal: Arterioscler Thromb Vasc Biol Date: 2012-12 Impact factor: 8.311